Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmesis InternationalSGX:BFK 31 Days Payable is 133.07 as of Dec. 2025, which is 142% above its 10-year median of 54.99. GuruFocus rates SGX:BFK with a GF Score™ of 31/100 and a GF Value™ of S$0.09 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 926 Drug Manufacturers companies, Pharmesis International ranks better than 81.86% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SGX:BFK vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pharmesis International's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmesis International Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pharmesis International's Days Payable distribution charts can be found below:
* The bar in red indicates where Pharmesis International's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Pharmesis International's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmesis International (SGX:BFK) has a Days Payable of 133.07 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pharmesis International and its competitors. This is 142% above median its historical median of 54.99. Over the past decade, Pharmesis International's Days Payable has ranged from 27.42 to 240.82. According to the industry distribution chart, Pharmesis International ranks #168 out of 926 companies in the Drug Manufacturers industry, placing it in the top 18.1%.
Is Pharmesis International's Days Payable too high?
Pharmesis International's current Days Payable of 133.07 is 142% above median its 10-year median of 54.99. Over the past 10 years, this metric has ranged from a low of 27.42 to a high of 240.82. The Drug Manufacturers industry median Days Payable is 90.22. Pharmesis International's value of 133.07 is 47.5% above this industry median. Based on the distribution chart, Pharmesis International ranks #168 out of 926 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Pharmesis International has a GF Score™ of 31/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pharmesis International's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Pharmesis International ranks #168 out of 926 companies for Days Payable. This places Pharmesis International in the top 18% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.22. Pharmesis International's value of 133.07 is 47.5% above this benchmark. Historically, Pharmesis International's own Days Payable has ranged from 27.42 to 240.82 over the past decade. While the company's 10-year median is 54.99 vs. the industry median of 90.22, Pharmesis International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.22, based on 926 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmesis International's current Days Payable of 133.07 is 47.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pharmesis International and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmesis International's current Days Payable is 133.07, which is 142% above median its own 10-year median of 54.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmesis International stock overvalued right now?
Based on GuruFocus' analysis, Pharmesis International (SGX:BFK) is currently considered Modestly Overvalued. The stock's GF Value™ is S$0.09, compared to a current price of S$0.11 — trading 18.9% above its estimated fair value. The current Days Payable is 133.07, which is 142% above median its 10-year median of 54.99 and 47.5% above the Drug Manufacturers industry median of 90.22. Pharmesis International's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Pharmesis International (SGX:BFK), the current Days Payable is 133.07 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmesis International (SGX:BFK) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmesis International stock appears to be overvalued.
The current stock price of S$0.11 is trading 18.9% above its estimated GF Value™ of S$0.09.
GuruFocus considers Pharmesis International to be Modestly Overvalued.
Key valuation signals for SGX:BFK:
Days Payable: 133.07 (142% above median its 10-year median of 54.99)
GF Value™: S$0.09 vs. price of S$0.11 (18.9% above fair value)
Industry Position: 47.5% above the Drug Manufacturers median (#168 of 926)
No single metric tells the full story. See the SGX:BFK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmesis International Ltd is an investment holding company. The company manufactures pharmaceutical products in the form of tablets, granules, pills, and other forms. Its operating segments are Western drugs/TCH Procurement, which are chemically formulated drugs and are marketed under the Kinna brand; TCM-formulated drugs/IP rental, which refer to Traditional Chinese Medicine and are marketed under the Longlife brand; and Distribution, which derives maximum revenue, refers to agency products and internally manufactured products which are marketed through the distribution arm. The company derives revenue from the sale of medicines to domestic customers in China.
31GF Score
Get the complete analysis for SGX:BFK
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:BFK has been successfully added to your 
